` EOLS (Evolus Inc) vs S&P 500 Comparison - Alpha Spread

EOLS
vs
S&P 500

Over the past 12 months, EOLS has underperformed S&P 500, delivering a return of -35% compared to the S&P 500's +14% growth.

Stocks Performance
EOLS vs S&P 500

Loading
EOLS
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
EOLS vs S&P 500

Performance Gap Between EOLS and GSPC
HIDDEN
Show

Performance By Year
EOLS vs S&P 500

Loading
EOLS
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Evolus Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Evolus Inc
Glance View

Market Cap
457.9m USD
Industry
Pharmaceuticals

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. The company is headquartered in Newport Beach, California and currently employs 167 full-time employees. The company went IPO on 2018-02-08. The Company’s first commercial product is Jeuveau, which is an approximately 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. The company offers customers and consumers a compelling value proposition with Jeuveau. BOTOX (onabotulinumtoxinA) is also an approximately 900 kDa botulinum toxin type A complex approved in the United States.

EOLS Intrinsic Value
HIDDEN
Show
Back to Top